Finerenone reduces risk of cardiac events in Diabetes with CKD: Study

"We are pleased to see that finerenone could provide a meaningful treatment option for patients who are battling chronic conditions," said Gerasimos Filippatos, M.D., the study's lead author and a professor of cardiology at the National and Kapodistrian University of Athens in Greece.

The FIDELIO-DKD study is a phase III, randomized, double-blind, placebo-controlled trial that enrolled nearly 6,000 patients (average age 66; 70.2% male) at more than 900 sites in 48 countries. The goal was to investigate finerenone in patients with chronic kidney disease and Type 2 diabetes since these patients face significant risk of cardiovascular disease and death. Cardiovascular events like heart attacks, heart failure and stroke are some of the leading causes of death in this patient group.

After follow-up of more than 2-1/2 years, researchers found a daily, oral treatment at 10 mg or 20 mg with finerenone reduced by 14% the risk of cardiovascular events for patients who already had a history of heart disease and for those who had no previous history. It also reduced the rate of death, heart attack, stroke and hospitalization for heart failure among patients with chronic kidney disease and Type 2 diabetes.

There are additional phase III trials of finerenone in progress.

Presentation: LBS.07 - Randomized Trials – Brain, Kidney, and Heart

Additional Resources:

• Multimedia is available on the right column of the release link https://newsroom.heart.org/news/new-medication-helps-heart-health-in-people-with-chronic-kidney-disease-type-2-diabetes?preview=e7ff33b3a00018838af1129f184ed152